Biographies

E-mail this page

(All fields required)

Recipient's email address

Please enter a valid email.

Your name

Please enter your name.

Your email address

Please enter a valid email.

Find another Doctor or Researcher

High Res

James C. Mulloy, PhD

Associate Professor, UC Department of Pediatrics

Phone: 513-636-1844

Fax: 513-636-3768

Email: james.mulloy@cchmc.org

Show All

Specialties

Visit the Mulloy Lab.

Education and Training

BA: St. Anselm College, Manchester, New Hampshire, 1986.

MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1989.

PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1992.

Publications

View PubMed Publications

Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. March;121:e90-e97. 2013.

Bell-Horwath, T. B., Vadukoot, A. K., Li, G.; Thowfeik, S., Wunderlich, M., Mulloy, JC, Merino, E. J. Novel oxidatively activated anticancer agents selectively target acute myeloid leukemia. Bioorganic & Medicinal Chemistry Letters 23:2951–2954, 2013.

Goyama S, Mulloy JC. Making healthy stem cells: the new role of TPO. Cell Stem Cell. Jan 3;12(1):8-9. 2013.

Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J, Saunthararajah Y.CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia, 26(2):244-54, Feb 2012.

Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S. Chromatin modifications induced by the AML1/ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia, 26(6):1329-37, Jun 2012.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJ, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J. miR-196b directly targets bothHOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun. 2:688. doi: 10.1038/ncomms1681. Feb 21 2012.

Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, Kurokawa M. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol. 42(4):1044-50. Apr 2012

Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC.The THPO/MPL/Bcl-xL pathway is essential for survival and self-renewal in human pre-leukemia induced by AML1-ETO. Blood,(plenary paper) 120 (4): 2012.

Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood, 120 (4): 2012.

Zhang Y, Yan X, Sashida G, Zhao X, Rao Y,Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, Grimes HL, Caligiuri MA, Huang G. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. Aug 2 2012; 120(5):1118-29. Epub 2012 Jun 26.

Grants

Targeting Cdc42 in leukemia stem cells. Co-Principal Investigator. National Cancer Institute. Apr 2010 - Mar 2015. #1R01CA150547-01.

Rac Signaling in MLL Leukemia. Principal Investigator. Leukemia and Lymphoma Society. Jul 2010 – Jun 2015.

Cincinnati Center of Excellence in Molecular Hematology. Co-Director, Animal Core. National Institutes of Health. Sep 2010 – Jul 2015. # P30 DK090971.

RUNX1 tumor suppressor as a therapeutic target in AML. Principal Investigator. Center for Clinical and Translational Science and Training, UC/CCHMC. Jul 2012 – Jun 2013.

The role of bone marrow microenvironment in a humanized MDS mouse model. Co-Principal Investigator. Innovation Grant (Mulloy/Cancelas). CCHMC. 09/01/12 – 08/31/13.

Genotype and phenotype of chemoresistant AML. Principal Investigator. NIH, NCI. 03/01/13 - 02/28/15. R21 CA168369.

Hemostatic system components as novel therapeutic targets in childhood AML. Co-Principal Investigator. Center for Clinical and Translational Science and Training (Palumbo/Mulloy). 07/01/13 – 06/30/14.

A Novel ROS-activated Therapeutic Modality for AML. Co-Principal Investigator. Center for Clinical and Translational Science and Training (Merino/Mulloy). 07/01/13 – 06/30/14.

Validation and structural requirements of a novel anti-leukemia agent. Co-Principal Investigator. UC Technology Commercialization Accelerator (Merino/Mulloy). University of Cincinnati. 04/01/13 – 03/31/14

Efficacy and selectivity in combination of novel ROS activated anticancer agent. Co-Principal Investigator. University Research Council-UC (Merino/Mulloy). Interdisciplinary Faculty Research Support Grant. 04/01/13 – 03/31/14

Human IFN- Neutralization in Humanized NSGS Mice Developing Cytopenias. Principal Investigator. NovImmune (Mulloy/Jordan). 03/01/13 – 02/28/14.

LSC mobilization and differentiation therapy. Co-Principal Investigator. Hyundai Hope On Wheels! (Mulloy/Mizukawa). 09/01/13 – 08/31/15.